Med. Pro Praxi 2009; 6(3): 122-125

The endocrine hypertension in primary care - focused od primary aldosteronism

MUDr. Ondřej Petrák, Ph.D, doc. MUDr. Tomáš Zelinka, CSc, MUDr. Branislav Štrauch, Ph.D, doc. MUDr. Robert Holaj, CSc, MUDr. Jan Rosa, prof. MUDr. Jiří Widimský jr., CSc
3. interní klinika VFN, Centrum pro diagnostiku a léčbu hypertenze, Praha

The endocrine hypertension represents one of the causes of secondary hypertension. The early recognition of the condition is important

as this condition may predispose to the increased mortality from cardiovascular disease, and is often reversible with target therapy. It is

necessary to consider this diagnose and in case of any suspicion send patients to a diagnostic centre. This part is focused on diagnostic

and therapeutic aspects of primary aldosteronism.

Keywords: endocrine hypertension, primary aldosteronism, aldosteron.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petrák O, Zelinka T, Štrauch B, Holaj R, Rosa J, Widimský J. The endocrine hypertension in primary care - focused od primary aldosteronism. Med. praxi. 2009;6(3):122-125.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 2006; 48(11): 2293-2300. Go to original source... Go to PubMed...
    2. Young WF, Jr. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003; 144(6): 2208-2213. Go to original source... Go to PubMed...
    3. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J, Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. Journal of human hypertension 2003; 17(5): 349-352. Go to original source... Go to PubMed...
    4. Mattsson C, Young WF, Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2(4): 198-208; quiz, 191 p following 230. Go to original source... Go to PubMed...
    5. Young WF. Primary aldosteronism: renaissance of a syndrome. Clinical endocrinology 2007; 66(5): 607-618. Go to original source... Go to PubMed...
    6. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19(1): 13-18. Go to original source... Go to PubMed...
    7. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33(2): 261-266. Go to original source... Go to PubMed...
    8. Weber KT. Heart-hitting tales of salt and destruction. The Journal of laboratory and clinical medicine 2000; 136(1): 7-13. Go to original source... Go to PubMed...
    9. Brown NJ. Aldosterone and end-organ damage. Current opinion in nephrology and hypertension 2005; 14(3): 235-241. Go to original source... Go to PubMed...
    10. Holaj R, Zelinka T, Wichterle D, Petrak O, Strauch B, Widimsky J, Jr. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. Journal of hypertension 2007; 25(7): 1451-1457. Go to original source... Go to PubMed...
    11. Sindelka G, Widimsky J, Haas T, Prazny M, Hilgertova J, Skrha J. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 2000; 108(1): 21-25. Go to original source...
    12. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005; 45(8): 1243-1248. Go to original source... Go to PubMed...
    13. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007; 30(2): 111-117. Go to original source... Go to PubMed...
    14. Boscaro M, Ronconi V, Turchi F, Giacchetti G. Diagnosis and management of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 2008; 15(4): 332-338. Go to original source... Go to PubMed...
    15. Widimský J. Hypertenze. 3. vyd. Praha: Triton, 2008: 519-524.
    16. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine reviews 2004; 25(2): 309-340. Go to original source... Go to PubMed...
    17. Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996; 131(6): 646-650. Go to original source... Go to PubMed...
    18. Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. The American surgeon 2005; 71(10): 864-869. Go to original source... Go to PubMed...
    19. Seeman T, Widimský J, Hampf M, Bernhardt R. Abolished nocturnal blood pressure fall in a boy with glucocorticoidremediable aldosteronism. Journal of human hypertension 1999; 13(12): 823-828. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.